Autosomal dominant familial spastic paraplegias (AD-FSP) are a group of genetically heterogeneous diseases characterised by a progressive spasticity of the lower limbs. Three loci have already been identified by genetic linkage studies on chromosomes 2p, 14q and 15q. Here we present linkage data from a large German family displaying AD-FSP with anticipation which confirms the existence of the FSP2 locus on chromosome 2p. The recombination events observed in our family define the critical region for the FSP2 gene to be within a 4-cM interval, flanked by markers D2S400 and D2S367. Moreover, clinical data from our family show evidence of anticipation, a phenomenon caused by trinucleotide expansion in several other neurodegenerative diseases.
The results of crossbreeding experiments between several strains of rats are reported. They show differences in the prevalence of iritis in the course of adjuvant disease as did the results we published in an earlier article. There are alterations which indicate a recessive heredity of the tendency to iritis. The contribution of genetic factors in the course of adjuvant arthritis has been confirmed by the present results.
Hooded rats react to intracutaneous injections of complete Freund's adjuvant with an adjuvant disease, which is externally perceivable by massive polyarthritis, by skin and ear nodules, and by other known symptoms. In contrast to Wistar rats, however, they show no tendency to develop clinically or histologically provable eye manifestations such as an uveitis anterior (adjuvant uveitis). This fact has been connected with the genetic differences between the two strains of rats.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.